Evidence map›Paper›PMID 41227294›Full record

ReviewCells2025

Modelling Osteoporosis in Pre-Clinical Research-Challenges, Trends and New Approaches.

Johannes Plank, Alexandra Damerau, Madison Skye Chacon, Paula Hoff, Frank Buttgereit, Moritz Pfeiffenberger

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Johannes PlankDepartment of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
Alexandra DamerauDepartment of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany.ORCID 0000-0001-6651-2963
Madison Skye ChaconDepartment of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
Paula HoffDepartment of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany.ORCID 0000-0001-7494-0845
Frank ButtgereitDepartment of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
Moritz PfeiffenbergerDepartment of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis is a bone disease characterized by low bone mass and changes in bone architecture, often leading to fractures and thereby decreased functional status in affected patients. About 200 million people worldwide suffer from osteoporosis, with women being affected earlier in life and more often than men. Various factors, such as genetic background, comorbidities, alcohol abuse, and medications such as glucocorticoids, are known to contribute to the development of osteoporosis. Due to the changing demographics, osteoporosis is becoming increasingly prevalent, and with this, the rate of fractures is expected to increase in the coming years. To investigate therapeutic options for treatment and to elucidate disease-causing mechanisms, various in vivo and in vitro osteoporosis models have been developed. In vivo models, in particular small animal models, remain the gold standard for osteoporosis research and the most used model to illustrate osteoporosis is the ovariectomized mouse. While in vivo models largely reflect the systemic and biological conditions, the transferability of findings to human patients is low and ethical concerns for laboratory animals must be considered. Thanks to tremendous technological improvements, such as on-a-chip platforms and high-end bioreactor systems, sophisticated in vitro models are of growing interest. These models offer the possibility of using complex cell systems, human cells from single donors, and 3D models, thus bridging the transferability gap, providing a platform for the introduction of personalized precision medicine, and ultimately replacing animal testing. Here, we summarize and discuss recent in vivo, in vitro, and in silico osteoporosis research approaches.

Indexed as

Models, BiologicalOsteoporosisAnimalsDisease Models, AnimalFemaleHumansin vitro modelsin vivo modelsosteoporosis

Identifiers

PMID41227294
PMCPMC12609975

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.